Approximately 2400 US patients present with Synchronous Colorectal Cancer Hepatic Metastases annually. These patients comprise 15-25% of new cases of colorectal cancer per year.
CAR-T cell therapy is a new modality of treatment with a unique mechanism of action. The therapy has specific, potentially fatal toxicities. This new therapy requires specialized knowledge to treat these patients in an appropriate manner ...
All courses are available to everyone.
Only physicians can receive C.M.E.